Carol H Wysham1, Patrick Lefebvre2, Dominic Pilon3, Marie-Hélène Lafeuille4, Bruno Emond5, Rhiannon Kamstra6, Michael Pfeifer7, Mei Sheng Duh8, Mike Ingham9. 1. Multicare Rockwood Clinic, 400 E 5th Ave, Suite 4 West, Spokane, WA 99202, USA. Electronic address: cwysham@rockwoodclinic.com. 2. Analysis Group, Inc., 1000 De La Gauchetière West, Suite 1200, Montréal, Québec H3B 4W5, Canada. Electronic address: Patrick.Lefebvre@analysisgroup.com. 3. Analysis Group, Inc., 1000 De La Gauchetière West, Suite 1200, Montréal, Québec H3B 4W5, Canada. Electronic address: Dominic.Pilon@analysisgroup.com. 4. Analysis Group, Inc., 1000 De La Gauchetière West, Suite 1200, Montréal, Québec H3B 4W5, Canada. Electronic address: Marie-Helene.Lafeuille@analysisgroup.com. 5. Analysis Group, Inc., 1000 De La Gauchetière West, Suite 1200, Montréal, Québec H3B 4W5, Canada. Electronic address: Bruno.Emond@analysisgroup.com. 6. Analysis Group, Inc., 1000 De La Gauchetière West, Suite 1200, Montréal, Québec H3B 4W5, Canada. 7. Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA. Electronic address: mpfeifer@its.jnj.com. 8. Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA 02199-7668, USA. Electronic address: Mei.Duh@analysisgroup.com. 9. Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA. Electronic address: mingham2@its.jnj.com.
Abstract
AIMS: The aims of this study were to assess glycemic control, weight loss, and durability of glycemic control in patients initiated on canagliflozin (CANA) versus sitagliptin (SITA). METHODS: Adults with type II diabetes mellitus initiated on CANA or SITA (index date) were identified from IQVIA™ Real-World Data Electronic Medical Records - US database (03/29/2012-04/30/2016). Inverse probability of treatment weighting accounted for baseline differences between cohorts. Outcomes were compared using weighted Cox regression and Kaplan-Meier curves and included time to reaching HbA1c thresholds (<7%[53 mmol/mol], <8%[64 mmol/mol], <9%[75 mmol/mol]), weight loss ≥5%, failure to maintain HbA1c below threshold, new antihyperglycemic (AHA) prescription, and failure to maintain HbA1c/new AHA prescription. RESULTS: Weighted cohorts were well balanced (NCANA = 14,542; NSITA = 15,151). CANA patients were 12-15% more likely to reach the HbA1c thresholds, 47% more likely to lose ≥5% of body weight, 31% less likely to have a new AHA prescription, 10-15% less likely to fail to maintain HbA1c, and 13-26% less likely to fail to maintain HbA1c or have a new AHA, versus SITA patients. CONCLUSIONS: CANA patients were more likely to reach HbA1c and weight loss thresholds and maintain HbA1c below threshold versus SITA patients, while being less likely to have a prescription for a new AHA, suggesting more durable glycemic control with CANA.
AIMS: The aims of this study were to assess glycemic control, weight loss, and durability of glycemic control in patients initiated on canagliflozin (CANA) versus sitagliptin (SITA). METHODS: Adults with type II diabetes mellitus initiated on CANA or SITA (index date) were identified from IQVIA™ Real-World Data Electronic Medical Records - US database (03/29/2012-04/30/2016). Inverse probability of treatment weighting accounted for baseline differences between cohorts. Outcomes were compared using weighted Cox regression and Kaplan-Meier curves and included time to reaching HbA1c thresholds (<7%[53 mmol/mol], <8%[64 mmol/mol], <9%[75 mmol/mol]), weight loss ≥5%, failure to maintain HbA1c below threshold, new antihyperglycemic (AHA) prescription, and failure to maintain HbA1c/new AHA prescription. RESULTS: Weighted cohorts were well balanced (NCANA = 14,542; NSITA = 15,151). CANApatients were 12-15% more likely to reach the HbA1c thresholds, 47% more likely to lose ≥5% of body weight, 31% less likely to have a new AHA prescription, 10-15% less likely to fail to maintain HbA1c, and 13-26% less likely to fail to maintain HbA1c or have a new AHA, versus SITA patients. CONCLUSIONS:CANApatients were more likely to reach HbA1c and weight loss thresholds and maintain HbA1c below threshold versus SITA patients, while being less likely to have a prescription for a new AHA, suggesting more durable glycemic control with CANA.